TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

Imatinib Mesylate (IM)

IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.

DRUG

TALL-104 cells

TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abiogen Pharma

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER